LiverLearning®: Hepatitis C SIG Paving the Road to Hepatitis C Elimination

This program will summarize key concepts in U.S. and global strategies to achieve hepatitis C elimination. Experts will address topics such as new universal screening recommendations, novel paradigms for care delivery beyond the specialty clinic, global strategies for microelimination, treatment as prevention in persons who inject drugs (PWID), and the latest updates on HCV vaccine development.

Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta‐analysis

Zoe N. Memel, Ashwini Arvind, Oluwatoba Moninuola, Lisa Philpotts, Raymond T. Chung, Kathleen E. Corey, Tracey G. Simon – 13 November 2020 – Hepatocellular carcinoma (HCC) is the third‐leading cause of cancer‐related death worldwide, with a growing incidence and poor prognosis. While some recent studies suggest an inverse association between aspirin use and reduced HCC incidence, other data are conflicting. To date, the precise magnitude of risk reduction—and whether there are dose‐dependent and duration‐dependent associations—remains unclear.

Hepatic Stellate Cell Regulation of Liver Regeneration and Repair

Laura J. Kitto, Neil C. Henderson – 13 November 2020 – The hepatic mesenchyme has been studied extensively in the context of liver fibrosis; however, much less is known regarding the role of mesenchymal cells during liver regeneration. As our knowledge of the cellular and molecular mechanisms driving hepatic regeneration deepens, the key role of the mesenchymal compartment during the regenerative response has been increasingly appreciated.

Letter to the Editor: Post–Liver Transplantation Sinusoidal Obstruction Syndrome and Immunosuppressive Drugs: Causality of Mycophenolate Mofetil or Tacrolimus?

Véronique Loustaud‐Ratti, Alicia Anneraud, Paul Carrier, Marilyne Debette‐Gratien, Anne De Muret, Mattias Tallegas, Hélène Barraud, Louise Barbier, Ephrem Salamé – 13 November 2020

Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection

Michel Bazinet, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Mark Anderson, Jeff Gersch, Vera Holzmayer, Carina Elsner, Adalbert Krawczyk, Mary C. Kuhns, Gavin Cloherty, Ulf Dittmer, Andrew Vaillant – 13 November 2020 – The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and hepatitis B surface antigen (HBsAg) loss/seroconversion in the REP 301 study (NCT02233075).

Impact of Payer Status on Delisting Among Liver Transplant Candidates in the United States

Krystal L. Karunungan, Yas Sanaiha, Roland A. Hernandez, Holly Wilhalme, Sarah Rudasill, Joseph Hadaya, Joseph DiNorcia, Peyman Benharash – 13 November 2020 – Although socioeconomic disparities persist both pre‐ and post‐transplantation, the impact of payer status has not been studied at the national level. We examined the association between public insurance coverage and waitlist outcomes among candidates listed for liver transplantation (LT) in the United States.

Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta‐Analysis

Mark R. Pedersen, Garrett Greenan, Sumant Arora, Arvind R. Murali, Marlyn J. Mayo – 13 November 2020 – After liver transplantation (LT), the role of ursodeoxycholic acid (UDCA) is not well characterized. We examine the effect of UDCA after LT in the prophylaxis of biliary complications (BCs) in all‐comers for LT and the prevention of recurrent primary biliary cholangitis (rPBC) in patients transplanted for PBC.

Subscribe to